In patients with cervical cancer, the presence of CD133 on CTCs numbers ≥ 2/ml after therapy was sufficient to mediate a better discrimination between patients with and without relapse resulting in differences in 6.5 years RFS rate of 73.7% (blue lines; Supplementary S3B). This evidence concerns the gene PROM1 and cervical cancer.